rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Agenus Inc.

AGEN · Nasdaq

Health CareBiotechnologyLeading

AGEN stood above a rising 150-day average in 15 of the last 52 weekly readings, including each of the last 13 weeks. It is 13.9% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
13 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
99 (+18)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders99+18 on the quarter
New · exited34 · 17
Reported value$43.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20262,564,884$7.8M+2,019,222+370.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,676,096$5.1M+235,864+16.4%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,427,587$4.4M+232,478+19.5%
Siren, L.L.C.unchanged · filed 13 Aug 20261,064,250$3.3M00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,035,040$3.2M+686,645+197.1%
MACKENZIE FINANCIAL CORPnew · filed 13 Aug 2026714,175$2.2M+714,175
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026448,383$1.4M+416,929+1325.5%
MARSHALL WACE, LLPreduced · filed 13 Aug 2026439,621$1.3M-248,582−36.1%
RAYMOND JAMES FINANCIAL INCadded · filed 14 Aug 2026430,078$1.3M+190,524+79.5%
GLOBEFLEX CAPITAL L Pnew · filed 12 Aug 2026418,581$1.3M+418,581
31 Mar 2024 – 30 Jun 2026
115496Mar 24Sep 24Jun 25Dec 25Jun 26

Everyone who traded it

Thomas L. Harrison Company insiderDirector · last 1 Oct 20260 · 0
Timothy Wright Company insiderDirector · last 1 Oct 20261 · 0
Garo H. Armen Company insiderDirector, Officer · last 10 Aug 202623 · 6
Brian Corvese Company insiderDirector · last 5 Aug 20260 · 0
Jennifer Buell Company insiderDirector, Officer · last 5 Aug 20260 · 1
Marco Tullio Marcucci Company insiderDirector · last 5 Aug 20260 · 0
Steven J. O'Day Company insiderChief Medical Officer · last 5 Aug 20260 · 1
Susan B. Hirsch Company insiderDirector · last 5 Aug 20260 · 0
Austin Charette Company insiderPrincipal Accounting Officer · last 24 Apr 20260 · 0
Christine M. Klaskin Company insiderPFO & PAO · last 18 Jun 20250 · 20
Ulf Wiinberg Company insiderDirector · last 1 Oct 20242 · 0
Allison M. Jeynes-Ellis Company insiderDirector · last 5 Feb 20240 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202599.1%
Operating profit marginFY 2025 · to 31 Dec 2025-17.7%
Free cash flow marginFY 2025 · to 31 Dec 2025-67.6%
Research spendFY 2025 · to 31 Dec 202569.5%
Share count trendFY 2025 · to 12 Mar 20268.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.0M
Free cash flowFY 2025 · to 31 Dec 2025−$77.2M

Analyst forecasts

No analyst forecasts yet.